NASDAQ:RCKT - Nasdaq - US77313F1066 - Common Stock - Currency: USD
2.33
-3.94 (-62.84%)
The current stock price of RCKT is 2.33 USD. In the past month the price decreased by -67.46%. In the past year, price decreased by -89.07%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.08 | 328.06B | ||
AMGN | AMGEN INC | 13.46 | 150.26B | ||
GILD | GILEAD SCIENCES INC | 14.09 | 135.70B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.53B | ||
REGN | REGENERON PHARMACEUTICALS | 13.61 | 65.13B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.83B | ||
ARGX | ARGENX SE - ADR | 98.77 | 35.40B | ||
ONC | BEIGENE LTD-ADR | 6.1 | 25.76B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.69B | ||
NTRA | NATERA INC | N/A | 21.46B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.04B | ||
BIIB | BIOGEN INC | 8.12 | 18.81B |
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 299 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
ROCKET PHARMACEUTICALS INC
9 Cedarbrook Drive
Cranbury NEW JERSEY 08512 US
CEO: Gaurav Shah
Employees: 299
Phone: 16464409100
The current stock price of RCKT is 2.33 USD. The price decreased by -62.84% in the last trading session.
The exchange symbol of ROCKET PHARMACEUTICALS INC is RCKT and it is listed on the Nasdaq exchange.
RCKT stock is listed on the Nasdaq exchange.
24 analysts have analysed RCKT and the average price target is 39.03 USD. This implies a price increase of 1575.19% is expected in the next year compared to the current price of 2.33. Check the ROCKET PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ROCKET PHARMACEUTICALS INC (RCKT) has a market capitalization of 251.03M USD. This makes RCKT a Micro Cap stock.
ROCKET PHARMACEUTICALS INC (RCKT) currently has 299 employees.
ROCKET PHARMACEUTICALS INC (RCKT) has a resistance level at 6.68. Check the full technical report for a detailed analysis of RCKT support and resistance levels.
The Revenue of ROCKET PHARMACEUTICALS INC (RCKT) is expected to grow by 115254% in the next year. Check the estimates tab for more information on the RCKT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RCKT does not pay a dividend.
ROCKET PHARMACEUTICALS INC (RCKT) will report earnings on 2025-08-04, after the market close.
ROCKET PHARMACEUTICALS INC (RCKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.63).
The outstanding short interest for ROCKET PHARMACEUTICALS INC (RCKT) is 12.11% of its float. Check the ownership tab for more information on the RCKT short interest.
ChartMill assigns a fundamental rating of 2 / 10 to RCKT. The financial health of RCKT is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months RCKT reported a non-GAAP Earnings per Share(EPS) of -2.63. The EPS increased by 8.36% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -54.77% | ||
ROE | -62.61% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 84% to RCKT. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of 12.95% and a revenue growth 115254% for RCKT